摘要
回顾性分析2020年10月至2021年11月在郑州大学附属肿瘤医院接受手术治疗的160例甲状腺乳头状癌患者资料。男37例,女123例,年龄(46.5±11.1)岁。BRAF^(V600E)突变率为86.3%(138/160);其突变与患者年龄(P=0.917)、肿瘤多灶性(P=0.673)、肿瘤大小(P=0.360)、肿瘤外侵(P=0.150)、区域淋巴结转移(P=0.406)均无明显相关性。针对甲状腺乳头状癌,尚不能以BRAF^(V600E)单一基因的突变来决定是否采取更积极的诊疗措施。
The current study analyzed the mutation rate of BRAF^(V600E)in papillary thyroid carcinoma patients and the correlation between BRAF^(V600E)mutation and aggressive biological behavior of papillary thyroid carcinoma.A total of 160 patients with papillary thyroid carcinoma who underwent surgical treatment in the Affiliated Cancer Hospital of Zhengzhou University from October 2020 to November 2021 were retrospectively included.All patients underwent BRAF^(V600E)gene detection.There were 37 males and 123 females,with a mean age of(46.5±11.1)years.The mutation rate of BRAF^(V600E)was 86.3%(138/160).There was no significant correlation between the mutation of BRAF^(V600E)and aggressive factors such as age(P=0.917),single focal/multifocal tumor(P=0.673),tumor size(P=0.360),tumor invasion(P=0.150)and regional lymph node metastasis(P=0.406).Therefore,for papillary thyroid cancer,mutations in a single gene like BRAF^(V600E)fail to determine more active diagnosis and treatment.
作者
周斌
黑虎
李艳青
张冬雁
王冬青
秦建武
Zhou Bin;Hei Hu;Li Yanqing;Zhang Dongyan;Wang Dongqing;Qin Jianwu(Department of Thyroid and Neck,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Molecular Pathology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,China)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2023年第14期1060-1063,共4页
National Medical Journal of China
基金
河南省医学科技攻关计划(201503184)
